Key result
Rotavirus vaccination with Rotarix and RotaTeq is associated with a small increased risk of intussusception, which must be considered within the context of their demonstrated benefits.
Why the study?
Does rotavirus vaccination increase the risk of intussusception?
Does rotavirus vaccination increase the risk of intussusception?
There is a small increased risk of intussusception following rotavirus vaccination, which must be weighed against the demonstrated benefits of the vaccines.
Small intussusception risk with rotavirus vaccines should not alter recommendations; leaves open further risk stratification research.
In 1999, the first rotavirus vaccine licensed in the USA was withdrawn 9 months after introduction due to an association with intussusception that was detected in post-licensure surveillance. This association prompted large clinical trials designed to ensure the safety of two current live oral rotavirus vaccines, RotaTeq and Rotarix, which have since been recommended for use worldwide. Following their introduction, post-licensure studies have focused not only on the effectiveness and impact of these vaccines, but also on continued surveillance for intussusception. Most recent evidence from several countries shows a small increased risk of intussusception following vaccination with Rotarix and RotaTeq within the context of their demonstrated benefits. This review summarizes the available data on the safety of rotavirus vaccines with regards to intussusception.
No takes yet. Share an insight, caveat, or question.
Rha et al. (2014) conducted a review in Intussusception. Rotavirus vaccination (Rotarix and RotaTeq) was evaluated on Intussusception. Rotavirus vaccination with Rotarix and RotaTeq is associated with a small increased risk of intussusception, which must be considered within the context of their demonstrated benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: